Next Article in Journal
Microsatellite Mutation Rate during Allohexaploidization of Newly Resynthesized Wheat
Next Article in Special Issue
MicroRNAs as Diagnostic Biomarkers in Gastric Cancer
Previous Article in Journal
Photoluminescence Intermittency from Single Quantum Dots to Organic Molecules: Emerging Themes
Previous Article in Special Issue
Phosphoproteomics and Lung Cancer Research
Article Menu

Export Article

Open AccessArticle
Int. J. Mol. Sci. 2012, 13(10), 12519-12532; doi:10.3390/ijms131012519

Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells

1
Laboratory of Veterinary Biochemistry and Immunology, College of Veterinary Medicine, Chungbuk National University, Cheongju 361-763, Korea
2
Medical Research Institute, College of Medicine, Chung-Ang University, Seoul 156-756, Korea
*
Author to whom correspondence should be addressed.
Received: 26 July 2012 / Revised: 18 September 2012 / Accepted: 21 September 2012 / Published: 28 September 2012
(This article belongs to the Special Issue Advances in Molecular Oncology (special issue))
View Full-Text   |   Download PDF [966 KB, uploaded 19 June 2014]   |  

Abstract

The risk of prostate cancer has been increasing in men by degrees. To develop a new prostate cancer therapy, we used a stem cell-derived gene directed prodrug enzyme system using human neural stem cells (hNSCs) that have a tumor-tropic effect. These hNSCs were transduced with the therapeutic genes for bacterial cytosine deaminase (CD), alone or in combination with the one encoding human interferon-beta (IFN-β) or rabbit carboxyl esterase (CE) to generate HB1.F3.CD, HB1.F3.CD.IFN-β, and HB1.F3.CE cells, respectively. CD enzyme can convert the prodrug 5-fluorocytosine (5-FC) into the activated form 5-fluorouracil (5-FU). In addition, CE enzyme can convert the prodrug CPT-11 into a toxic agent, SN-38. In our study, the human stem cells were found to migrate toward LNCaP human prostate cancer cells rather than primary cells. This phenomenon may be due to interactions between chemoattractant ligands and receptors, such as VEGF/VEGFR2 and SCF/c-Kit, expressed as cancer and stem cells, respectively. The HB1.F3.CE, HB.F3.CD, or HB1.F3.CD.IFN-β cells significantly reduced the LNCaP cell viability in the presence of the prodrugs 5-FC or CPT-11. These results indicate that stem cells expressing therapeutic genes can be used to develop a new strategy for selectively treating human prostate cancer. View Full-Text
Keywords: human stem cells; prostate cancer; cytosine deaminase; interferon-beta; carboxyl esterase; tumor-tropism human stem cells; prostate cancer; cytosine deaminase; interferon-beta; carboxyl esterase; tumor-tropism
This is an open access article distributed under the Creative Commons Attribution License (CC BY 3.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Yi, B.-R.; Hwang, K.-A.; Kim, Y.-B.; Kim, S.U.; Choi, K.-C. Effects of Genetically Engineered Stem Cells Expressing Cytosine Deaminase and Interferon-Beta or Carboxyl Esterase on the Growth of LNCaP Prostate Cancer Cells. Int. J. Mol. Sci. 2012, 13, 12519-12532.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top